News and information on branded drugs sold in retail pharmacies, as well as their suppliers.
As it moves into its second century in business, Upsher-Smith Labs is focusing on innovating and growing its product offerings while maintaining its high standards.
Neurelis’ Valtoco is the first and only nasal spray treatment for seizure cluster rescue in adult and pediatric patients age 6 years old and older.
Lundbeck’s Vyepti is the first and only intravenous preventive treatment for migraine.
Biohaven's Nurtec ODT is a single quick-dissolving oral tablet for adult patients with acute migraine.
Seqirus' Fluad Quadrivalent vaccine offers flu protection for adults 65 years old and older.
Sun Pharma’s Riomet ER is the first and only liquid formulation of metformin for Type 2 diabetes patients.
Sanofi-Aventis' Sarclisa works by helping certain cells in the immune system attack multiple myeloma cancer cells.
The FDA has approved Palforzia, the first treatment for peanut allergy in children.
Sun Pharma's Absorica LD features a special formulation of active ingredient isotretinoin meant to optimize absorption at a 20% lower dose.
Allergan is offering Ubrelvy for the acute treatment of migraine with or without aura in adults.
Eagle has exclusive rights to commercialize Pemfexy for four months beginning Feb. 1, 2022, with an uncapped entry into the market expected on April 1, 2022.
Fresenius Kabi's glucagon emergency kit provides a treatment for severe hypoglycemia in pediatric and adult patients with diabetes.
Ajovy offers patients the flexibility of quarterly 675 mg or monthly 225 mg dosing options.
Valtoco is the first nasal spray approved by the Food and Drug Administration as a rescue treatment for people with epilepsy age 6 years old and older.